Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus

Journal of Immunology

Volumn 163, Issue 10, 1999, Pages 5512-5518

  Solache, Alejandra ^a,b   Morgan, Claire L ^b   Dodi, Anthony I ^b   Morte, Carles ^b   Scott, Iain ^b   Baboonian, Christina ^c   Zal, Behnam ^c   Goldman, John ^d   Grundy, Jane E ^b   Madrigal, J Alejandro ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; VIRUS PROTEIN; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; EPITOPE; HLA A2 ANTIGEN; MATRIX PROTEIN; PEPTIDE FRAGMENT; PHOSPHOPROTEIN;

AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; EPITOPE MAPPING; HOST RESISTANCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STRAIN DIFFERENCE; ANTIGEN PRESENTATION; CELL LINE; CHEMISTRY; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOCYTE ACTIVATION; METABOLISM; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; SPECIES DIFFERENCE;

ANTIGEN PRESENTATION; CELL LINE; CELL LINE, TRANSFORMED; CONSERVED SEQUENCE; CYTOMEGALOVIRUS; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; PEPTIDE FRAGMENTS; PHOSPHOPROTEINS; PROTEIN BINDING; SPECIES SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS;

EID: 0033570373     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Borysiewicz, L., J. Hickling, S. Graham, J. Sinclair, M. Cranage, G. Smith, and J. Sissons. 1988. Human-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J. Exp. Med. 168:919.
2. Reusser, P., S. Riddell, J. Meyers, and P. Greenberg. 1991. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78:1373.
3. Quinnan G. V. J., N. Kirmani, A. Rook, J. Manischewitz, L. Jackson, G. Moreschi, G. Santos, R. Saral, and W. Burns. 1982. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N. Engl. J. Med. 307:7.
4. Riddell, S., M. Rabin, A. Geballe, W. Britt, and P. Greenberg. 1991. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J. Immunol. 146:2795.
5. Wills, M., A. Carmichael, K. Mynard, X. Jin, M. Weekes, B. Plachter, and J. Sissons. 1996. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J. Virol. 70:7569.
6. Gibson, W., and A. Irmiere. 1984. Selection of particles and proteins for use as human cytomegalovirus subunit vaccines. Birth Defects 20:305.
7. + virus-specific cytotoxic T lymphocytes. J. Med. Virol. 43:103.
8. Diamond, D., J. York, J. Sun, C. Wright, and S. Forman. 1997. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90:1751.
9. Weekes, M. P., M. R. Wills, K. Mynard, A. J. Carmichael, and J. G. Sissons. 1999. The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo. J. Virol. 73:2099.
10. Gammon, G., N. Shastri, J. Cogswell, S. Wilbur, S. Sadegh-Nasseri, U. Krzych, A. Miller, and E. Sercarz. 1987. The choice of T-cell epitopes utilized on a protein antigen depends on multiple factors distant from, as well as at the determinant site. Immunol. Rev. 98:53.
11. Bertoletti, A., A. Sette, F. Chisari, A. Penna, M. Levrero, M. De Carli, F. Fiaccadori, and C. Ferrari. 1994. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369:407.
12. + population. Science 260:98.
13. Klenerman, P., U. Meier, R. Phillips, and A. McMichael. 1995. The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. Eur. J. Immunol. 25:1927.
14. Moskophidis, D., and R. Zinkernagel. 1995. Immunobiology of cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus. J. Virol. 69:2187.
15. Falk, K., O. Rotzschke, S. Stevanovic, G. Jung, and H. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290.
16. Parker, K., M. Bednarek, and J. Coligan. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152:163.
17. Rammensee, H., T. Friede, and S. Stevanovic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178.
18. Imanishi, T., T. Akaz, A. Kimura, K. Tokunaga, and T. Gojobori. 1991. Allele and haplotype frequencies for HLA and Complement loci in various ethnic groups. In HLA 1991, Vol. 1. K. Tsuji, M. Aizawa, and T. Sasazuki, eds. Oxford University Press, p. 1065.
19. Salter, R., and P. Cresswell., 1986. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J. 5:943.
20. Tiercy, J., N. Djavad, N. Rufer, D. Speiser, M. Jeannet, and E. Roosnek. 1994. Oligotyping of HLA-A2, -A3, and -B44 subtypes: detection of subtype incompatibilities between patients and their serologically matched unrelated bone marrow donors. Hum. Immunol. 41:207.
21. Craigen, J., and J. Grundy. 1996. Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment. Transplantation 62:1102.
22. Wilkinson, G., and A. Akrigg. 1992. Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res. 20:2233.
23. Sette, A., S. J. M. del Guerco, S. Southwood, J. Ruppert, C. Dalbergh, H. Grey, and R. Kubo. 1994. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative binding assays. Mol. Immunol. 31:813.
24. Burg, S., E. Ras, J. Drijfhout, W. Benkuijsen, A. J. Bremers, C. Melief, and W. Kast. 1995. An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B-cells: identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. Hum. Immunol. 44:189.
25. Burg, S., M. Visseren, R. Brandt, W. Kast, and C. Melief. 1996. Immunogenicity of peptides bound to MHC Class I molecules depends on the MHC-peptide complex stability. J. Immunol. 156:3308.
26. Elvin, J., V. Cerundulo, T. Elliot, and A. Townsend. 1991. A quantitative assay of peptide-dependent class I assembly. Eur. J. Immunol. 21:2005.
27. Parham, P., C. Barnstable, and W. Bodmer. 1979. Use of monoclonal antibody (W6/32) in structural studies of HLA-A, B, C antigens. J. Immunol. 123:342.
28. Barnstable, C. J. 1978. Production of monoclonal antibodies against group A erythrocytes, HLA and other human cell surface antigens new tools for genetic analysis. Cell 14:9.
29. Morgan, C. L., A. K. Ruprai, A. Solache, M. Lowdell, C. P. Price, S. B. A. Cohen, P. Parham, A. Madrigal, and D. J. Newman. 1998. The influence of exogenous peptide on β2-microglobulin exchange in the HLA complex: analysis in real time. Immunogenetics 48:98.
30. Sugawara, S., T. Abo, K. Kumagai, 1987. A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3. J. Immunol. Methods 100:83.
31. Townsend, A., J. B. Rothbard, F. M. Gotch, G. Bahadur, D. Wraith, and A. J. McMichael. 1986. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44:959.
32. McCutcheon, M., N. Wehner, A. Wensky, M. Kushner, S. Doan, L. Hsiao, P. Calabresi, T. Ha, T. V. Tran, K. M. Tate, et al. 1997. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J. Immunol. Methods 210: 149.
33. Ruger, B., S. Klages, B. Walla, J. Albrecht, B. Fleckenstein, P. Tomlinson, and B. Barrell. 1987. Primary structure and transcription of the genes coding for the two virion phosphoproteins pp65 and pp71 of human cytomegalovirus. J. Virol. 61:446.
34. DeMars, R., R. Rudersorf, C. Chang, J. Peterson, J. Strandtmann, N. Korn, B. Sidwell, H.T. Orr, 1985. Mutations that impair a posttranscriptional step in expression of HLA-A and -B antigens. Proc. Natl. Acad. Sci. USA 82:8183.
35. Bednarek, M., A. Sauma, M. Gammon, G. Porter, S. Tamhankair, A. Williamson, and H. Zweerink. 1991. The minimum peptide epitope from the influenza virus matrix protein: extra and intracellular loading of HLA-A2. J. Immunol. 147:4047.
36. Gotch, F., J. Rothbard, K. Howland, A. Townsend, and A. McMichael, 1987. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature 326:881.
37. Cerundulo, V., J. Alexander, K. Anderson, C. Lambi, P. Cresswell, A. McMichael, F. Gotch, and A. Townsend, 1990. Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature 345:449.
38. Celis, E., V. Tsai, C. Crimi, R. DeMars, P. Wentworth, R. Chesnut, H. Grey, A. Sette, and H. Serra. 1994. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA 91:2105.
39. Schild, H., M. Norda, K. Deres, K. Falk, O. Rotzschke, K. Wiesmuller, G. Jung, and H. Rammensee. 1991. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide. J. Exp. Med. 174:1665.
40. Jochmus, I., W. Osen, A. Altmann, G. Buck, B. Hofmann, A. Schneider, L. Gissmann, and H. Rammensee. 1997. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide. J. Gen. Virol. 78 :1689.
41. Riddell, S., P. Reusser, and P. Greenberg. 1991. Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients. Rev. Infect. Dis. 13(Suppl. 11):S966.
42. Pande, H., S. Baak, A. D. Riggs, B. R. Clark, J. Shively, and J. A. Zaia. 1984. Cloning and physical mapping of a gene fragment coding for a 64-kilodalton major late antigen of human cytomegalovirus. Proc. Natl. Acad. Sci. USA 81: 4965.
43. Hengel, H., T. Flohr, G. Hammerling, U. Koszinowski, and F. Momburg. 1996. Human cytomegalovirus inhibits peptide translocation into the endoplasmic reticulum for MHC class I assembly. J. Gen. Virol. 77:2287.
44. Jones, T., L. Hanson, L. Sun, J. Slater, R. Stenberg, and A. Campbell. 1995. Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. J. Virol. 69:4830.
45. Ahn, K., A. Gruhler, B. Galocha, T. Jones, E. Wiertz, H. Ploegh, P. Peterson, Y. Yang, and K. Fruh. 1997. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 6:613.
46. Gilbert, M., S. Riddell, C. R. Li, and P. Greenberg. 1993. Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J. Virol. 67:3431.
47. Tsomides, T. J., B. D. Walker, and H. N. Einsen. 1991. An optimal viral peptide recognized by CD8+ T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. Proc. Natl. Acad. Sci. USA 88:11276.